AVTR
HealthcareAvantor, Inc. · Medical - Instruments & Supplies · $6B
What is Avantor, Inc.?
Avantor, Inc. is a global supplier of mission-critical products and services to the biopharma, healthcare, education, and advanced materials industries. It operates across the Americas, Europe, Asia, the Middle East, and Africa.
Avantor generates revenue by supplying purity chemicals, lab consumables, equipment, and specialty services to research and production customers. It also provides onsite lab support, clinical trial logistics, and biopharmaceutical scale-up services — making it a broad-based partner across the life sciences supply chain.
Avantor went public in 2019 and is headquartered in Radnor, Pennsylvania.
- Purity chemicals, reagents, and lab consumables
- Filtration, bioprocessing, and analytical instrumentation
- Single-use assemblies and process chromatography products
- Onsite lab services and clinical trial support
Is AVTR a Good Stock to Buy?
UQS Score rates AVTR as Below Average overall.
Among the five pillars, Valuation stands out as the relative bright spot, rated Good — suggesting the market may already be pricing in the company's current challenges.
Quality, Moat, Growth, and Risk all carry Weak ratings, reflecting broad fundamental headwinds across profitability, competitive positioning, and balance sheet health.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AVTR pay dividends?
No — Avantor, Inc. does not currently pay a dividend.
Avantor does not currently pay a dividend. The company appears to prioritize reinvestment and debt management over returning cash to shareholders — a common stance for businesses navigating a post-acquisition integration phase.
When does AVTR report earnings?
Avantor reports earnings on a quarterly cadence, typical for US-listed equities.
The company has faced revenue headwinds in recent periods, particularly in its biopharma end markets, as customer destocking weighed on demand. Recovery progress has been gradual and uneven across segments.
For the most recent quarter's results, visit Avantor's investor relations page directly.
AVTR Price History
-73.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Avantor, Inc.?
Based on Avantor, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Avantor do?
Avantor supplies chemicals, lab products, equipment, and services to biopharma, healthcare, and advanced materials customers worldwide. It also provides onsite lab support, clinical trial logistics, and bioprocessing solutions, acting as an integrated partner across the life sciences supply chain.
Does AVTR pay dividends?
No, Avantor does not currently pay a dividend. The company focuses on reinvestment and managing its debt load rather than distributing cash to shareholders.
When does AVTR report earnings?
Avantor follows a standard quarterly earnings schedule. For the exact dates of upcoming reports, check the investor relations section of Avantor's official website.
Is AVTR a good stock to buy?
UQS Score rates AVTR as Below Average, with Weak ratings across Quality, Moat, Growth, and Risk pillars. The Valuation pillar is rated Good. Investors should weigh the fundamental challenges against the relative valuation before making any decision.
Is AVTR overvalued?
The UQS Valuation pillar for AVTR is rated Good, suggesting the stock is not considered expensive relative to its fundamentals at current levels. The full valuation breakdown is available to Pro members.
What is AVTR's market cap bracket?
Avantor is classified as a mid-cap stock. This places it in a range that typically offers more liquidity than small-caps while remaining more volatile than large-cap peers.
Is AVTR a long-term quality indicator?
Based on UQS pillar ratings, AVTR currently shows Weak scores across Quality, Moat, and Growth — the pillars most associated with long-term compounding potential. The Valuation pillar being rated Good may offer some cushion, but the overall profile warrants caution for long-horizon investors.
What sector does AVTR belong to?
Avantor operates in the Healthcare sector, specifically within life sciences tools and services. It serves biopharma, clinical, and advanced materials customers across global markets.
Unlock Full AVTR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete pillar-by-pillar score breakdown for AVTR
- ✓Access detailed financial metrics behind each rating
- ✓Compare AVTR against sector peers on every pillar
- ✓Track score changes as new earnings data is released
Pro Analysis
AVTR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 39.7 | 24.2 | 24.0 | 25.5 | 70.7 | 79.6 | 0.0 |
| May 17, 2026 | 39.7 | 24.2 | 24.0 | 25.5 | 70.7 | 79.8 | 0.0 |
| May 16, 2026 | 39.7 | 24.2 | 24.0 | 25.4 | 70.7 | 79.8 | 0.0 |
| May 14, 2026 | 39.7 | 24.2 | 24.0 | 25.4 | 70.7 | 79.6 | +0.2 |
| May 13, 2026 | 39.5 | 23.6 | 24.0 | 25.4 | 70.7 | 79.4 | 0.0 |
| May 12, 2026 | 39.5 | 23.6 | 24.0 | 25.4 | 70.7 | 79.6 | 0.0 |
| May 11, 2026 | 39.5 | 23.6 | 24.0 | 25.4 | 70.7 | 79.3 | +2.0 |
| May 10, 2026 | 37.5 | 19.4 | 24.0 | 25.2 | 70.7 | 73.3 | -2.0 |
| May 8, 2026 | 39.5 | 23.6 | 24.0 | 25.2 | 70.7 | 79.3 | -0.1 |
| May 7, 2026 | 39.6 | 24.2 | 24.0 | 25.2 | 70.7 | 79.2 | 0.0 |
AVTR — Pillar Breakdown
Quality
— 24.2/100 (25%)Avantor, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 25.5/100 (20%)Avantor, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 70.7/100 (15%)Avantor, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 79.5/100 (15%)Avantor, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 24/100 (25%)Avantor, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AVTR.
Score Composition
Financial Data
More Stock Analysis
How is the AVTR UQS Score Calculated?
The UQS (Unified Quality Score) for Avantor, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Avantor, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Avantor, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.